Roble Belko & Company’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Roble Belko & Company’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,502	Closed	–	–	391
2024 Q1	$0	Hold	4,502	–	–	﹤0.01%	379
2023 Q4	$0	Hold	4,502	–	–	﹤0.01%	360
2023 Q3	$0	Hold	4,502	–	–	﹤0.01%	334
2023 Q2	$0	Hold	4,502	–	–	﹤0.01%	340
2023 Q1	$1K	Hold	4,502	–	–	﹤0.01%	288
2022 Q4	$5K	Hold	4,502	–	–	﹤0.01%	274
2022 Q3	$9K	Hold	4,502	–	–	﹤0.01%	251
2022 Q2	$7K	Hold	4,502	–	–	﹤0.01%	256
2022 Q1	$23K	Hold	4,502	–	–	﹤0.01%	227
2021 Q4	$28K	Buy	+4,502	New	+$40.2K	0.01%	188

Roble Belko & Company's PEAR Position: Q2 2024 in Review

Roble Belko & Company sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2024, closing a stake of 4,502 shares.

Roble Belko & Company first reported a position in PEAR in Q4 2021 and held it in 10 quarters. The position peaked at $28K in Q4 2021. 0 funds tracked by Wall St. Rank hold PEAR as of Q2 2024.

Roble Belko & Company reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2024 after selling out during the quarter.
Roble Belko & Company sold 4,502 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2024.
Roble Belko & Company first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q4 2021 and held it in 10 quarters.
Roble Belko & Company's Pear Therapeutics, Inc. Class A Common Stock position peaked at $28K in Q4 2021.
0 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2024.

Based on Roble Belko & Company's 13F filing for Q2 2024, filed 8 Aug 2024.